Learn More about ConcertAI's CARAai™
Turn complex oncology data into actionable insights with CARAai™ - ConcertAI's intelligence layer for smarter decisions across clinical, commercial, and patient care.
CARAai knows healthcare data and how to translate it into enterprise-wide value for life sciences users
CARAai extracts key oncology variables like treatment response, metastatic status, stage, and ECOG with high accuracy. These models are trained and validated on millions of hours of cancer-specific data to ensure clinical relevance and precision.
CARAai interprets implicit and ambiguous clinical references -- like timing, comorbidities, and adverse events - with exceptional contextual accuracy. It translates messy, real-world documentation into structured insights that mirror physician logic.
Designed to handle fragmented and unstructured information, CARAai parses notes, radiology reports, and labs with equal fluency. Its versatility ensures nothing gets lost across specialties, formats, or care settings.
Reduce time from question to answer with intelligent, explainable AI built directly into your data environment.
Unlock new layers of meaning in unstructured EMR, pathology reports, and logitudinal records.
Drive better commercial, medical, and clinical strategies by knowing who is at risk, who qualifies, and what comes next.
CARAai powers every ConcertAI platform - from discovery and trials to commercialization and decision support.
Spend Time on Insight
Context That Drives Clarity
Agents That Drive Impact
ConcertAI is really the idea of virtualizing, if you will, clinical trials … You can actually build a much better strategy for your clinical trials—deciding which sites to choose, predicting what patients and populations you’ll need, and determining the likely outcomes of these trials. Reasoning is happening throughout all of these layers—integrating chat interfaces across many different domains within the complex clinical trial process. This enables everyone along the chain of clinical trials to benefit and accelerate decision-making, because every day a trial isn’t started is a massive opportunity lost for that drug to reach the market.